CAR-T cells monitoring clinical trials

Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells

This study looks at a faster way to check for leftover lymphoma cells after CAR-T cell treatment. By testing blood for tiny bits of cancer DNA, doctors hope to catch the disease coming back sooner and offer earlier extra treatment to improve patient outcomes.